EP4171539A4 - Compositions and methods for treating alzheimer's disease and parkinson's disease - Google Patents

Compositions and methods for treating alzheimer's disease and parkinson's disease

Info

Publication number
EP4171539A4
EP4171539A4 EP20942038.9A EP20942038A EP4171539A4 EP 4171539 A4 EP4171539 A4 EP 4171539A4 EP 20942038 A EP20942038 A EP 20942038A EP 4171539 A4 EP4171539 A4 EP 4171539A4
Authority
EP
European Patent Office
Prior art keywords
disease
parkinson
compositions
methods
treating alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20942038.9A
Other languages
German (de)
French (fr)
Other versions
EP4171539A1 (en
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA Pharmatech Inc
Original Assignee
LA Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LA Pharmatech Inc filed Critical LA Pharmatech Inc
Publication of EP4171539A1 publication Critical patent/EP4171539A1/en
Publication of EP4171539A4 publication Critical patent/EP4171539A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
EP20942038.9A 2020-06-26 2020-06-26 Compositions and methods for treating alzheimer's disease and parkinson's disease Pending EP4171539A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/039916 WO2021262196A1 (en) 2020-06-26 2020-06-26 Compositions and methods for treating alzheimer's disease and parkinson's disease

Publications (2)

Publication Number Publication Date
EP4171539A1 EP4171539A1 (en) 2023-05-03
EP4171539A4 true EP4171539A4 (en) 2024-01-17

Family

ID=79281652

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20942038.9A Pending EP4171539A4 (en) 2020-06-26 2020-06-26 Compositions and methods for treating alzheimer's disease and parkinson's disease

Country Status (5)

Country Link
EP (1) EP4171539A4 (en)
JP (1) JP2023539405A (en)
CN (1) CN115776885A (en)
CA (1) CA3183560A1 (en)
WO (1) WO2021262196A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010260808A (en) * 2009-05-01 2010-11-18 Ikeda Mohando:Kk Oral medicinal composition for improving skin condition
US20190030061A1 (en) * 2016-03-01 2019-01-31 Nova Southeastern University Cobalamin compositions and use thereof for improving cognitive function
US10639316B1 (en) * 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
HUE031470T2 (en) * 2004-11-24 2017-07-28 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods of use thereof
WO2007061454A1 (en) * 2005-11-22 2007-05-31 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010260808A (en) * 2009-05-01 2010-11-18 Ikeda Mohando:Kk Oral medicinal composition for improving skin condition
US20190030061A1 (en) * 2016-03-01 2019-01-31 Nova Southeastern University Cobalamin compositions and use thereof for improving cognitive function
US10639316B1 (en) * 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Parkinson's disease
US10639314B1 (en) * 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 *
See also references of WO2021262196A1 *

Also Published As

Publication number Publication date
CA3183560A1 (en) 2021-12-30
CN115776885A (en) 2023-03-10
JP2023539405A (en) 2023-09-14
EP4171539A1 (en) 2023-05-03
WO2021262196A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
EP4171539A4 (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
EP4196113A4 (en) Pharmaceutical compositions and methods for treating parkinson's disease
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
MX2019002211A (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders.
EP3927710A4 (en) Compositions and methods for treating or preventing alzheimer's disease
IL277182A (en) Compositions and methods for treating parkinson's disease
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
MX2020002884A (en) Method and improved neuroprotective composition for treating neurological conditions.
EP3880809A4 (en) Compositions and methods for treating wilson's disease
EP3773547A4 (en) Identification of granins as the pathogenic factor of alzheimer's disease and compositions and methods for inhibiting granin aggregation and treating alzheimer's disease
IL288894A (en) Methods for evaluation and treatment of alzheimer's disease and applications thereof
EP4028038A4 (en) Peptide-based compositions and methods for treating alzheimer's disease
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
EP3554496A4 (en) Methods and compositions for treating parkinson's disease
EP4037696A4 (en) Compositions and methods for treating alzheimer's disease
EP3998071A4 (en) Composition comprising o-cyclic phytosphingosine-1-phosphate for preventing or treating parkinson's disease
EP2214488A4 (en) Compositions and methods for treating parkinson's disease and related disorders
EP3802568A4 (en) Peptide therapeutics for treating alzheimer's disease and related conditions
EP3610879A4 (en) Composition for treatment and/or prevention of alzheimer's disease
IL309468A (en) Biomarkers for alzheimer's disease treatment
KR102467285B9 (en) Pharmaceutical Composition Comprising Woohuangchengsimhwan for Preventing or Treating Parkinson's Disease
IL265656A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
GB202016425D0 (en) Treatment regimens for parkinson's disease
IL282562A (en) Composition and use for the treatment of parkinson's disease and related disorders
EP3628008A4 (en) Compositions and methods for treating alzheimer's disease

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20231214BHEP

Ipc: A61P 25/14 20060101ALI20231214BHEP

Ipc: A61K 9/24 20060101ALI20231214BHEP

Ipc: A61K 9/20 20060101ALI20231214BHEP

Ipc: A61K 31/192 20060101AFI20231214BHEP